The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease

Charité University Medicine Berlin

Status: Completed

Conditions: Alzheimer Disease; Cognitive Dysfunction; Dementia; Blood Brain Barrier

Treatments: Diagnostic Test: Contrast agent enhanced MRI using Gadovist

Study type: Observational

Funder types: Other

Identifiers

NCT04093882

BHSkog

Details and patient eligibility

About

This study attempts to replicate the findings published in Nature Medicine by Nation and colleagues (2019). By using a large observational cohort (DZNE - Longitudinal Cognitive Impairment and Dementia Study; DELCODE) consisting of cognitively healthy individuals, individuals with subjective cognitive decline, mild cognitive impairment, and dementia due to Alzheimer's disease, an association between the blood-brain barrier and cognitive dysfunction is investigated. The integrity of the blood-brain barrier is investigated by using a novel MRI protocol as well as a novel biomarker in the cerebrospinal fluid.

Enrollment: 101 patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

• ≥ 50 years with neuropsychologically confirmed no cognitive dysfunction, mild cognitive impairment or mild dementia

Exclusion cirteria:

• no current or prior history of any neurological or psychiatric condition, which might affect cognitive function
• no neurodegenerative disease other than AD
• specifically no extensive vascular white matter dementia or vascular dementia

Trial design

101 participants in 3 patient groups

Cognitive normal

Description:

Individuals who do not show clinical or neuropsychological deficits.

Treatment:

Diagnostic Test: Contrast agent enhanced MRI using Gadovist

Mild cognitive impairment

Description:

Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.

Treatment:

Diagnostic Test: Contrast agent enhanced MRI using Gadovist

Dementia due to Alzheimer's disease

Description:

Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.

Treatment:

Diagnostic Test: Contrast agent enhanced MRI using Gadovist